Cancer Chemotherapy and Biological Response Modifiers, Annual 16 (16)

(2)
Cancer Chemotherapy and Biological Response Modifiers, Annual 16 (16) image
ISBN-10:

0444823263

ISBN-13:

9780444823267

Released: Jan 01, 1996
Format: Hardcover, 686 pages

Description:

Like its predecessors in this annual series, offers critical reviews of recent major developments in pharmacology of anti-cancer agents, the area of biologicals, and clinical management of the cancer patient. Nine contributions in the first section discuss drugs antimetabolites, alkylating agents, bleomycin, mitomycins, taxanes, DNA topoisomerase inhibitors, cisplatin, and multidrug resistance. The following seven contributions discuss biological response modifiers monoclonal antibody therapy, cytokines and immunological monitoring, adoptive immunotherapy, gene therapy, hematopoietic growth factors, reference databases of cytokine structure and function. The third section comprises 14 contributions on various kinds of tumors. Annotation c. by Book News, Inc., Portland, Or.

Best prices to buy, sell, or rent ISBN 9780444823267




Related Books

Frequently Asked Questions about Cancer Chemotherapy and Biological Response Modifiers, Annual 16 (16)

You can buy the Cancer Chemotherapy and Biological Response Modifiers, Annual 16 (16) book at one of 20+ online bookstores with BookScouter, the website that helps find the best deal across the web. Currently, the best offer comes from and is $ for the .

The price for the book starts from $7.98 on Amazon and is available from 3 sellers at the moment.

If you’re interested in selling back the Cancer Chemotherapy and Biological Response Modifiers, Annual 16 (16) book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.

As for the Cancer Chemotherapy and Biological Response Modifiers, Annual 16 (16) book, the best buyback offer comes from and is $ for the book in good condition.

Not enough insights yet.

Not enough insights yet.